论文部分内容阅读
目的:评价托吡酯快速加量法治疗癫癎发作对病人的安全性影响。方法:将130例癫癎病人分成两组。一组为常规加量组,另一组为快速加量组。常规加量组为每周加25 mg,4～8周达到治疗量,快速加量组为每3天加25 mg,在10～20 d达到治疗量。分别观察其不良反应出现的时间、频度、分级和严重程度。结果:快速加量组和常规加量组的不良反应发生率分别为41.54％和38.46％,而且其持续时间均相近。结论:托吡酯的快速加量法是安全的。
Objective: To evaluate the effect of topiramate fast-acting therapy on the safety of patients with epileptic seizures. Methods: 130 epileptic patients were divided into two groups. One group was a regular dose group and the other was a fast dose group. The conventional dosage group was 25 mg weekly, and the therapeutic dose was reached after 4 to 8 weeks. The fast dosage group added 25 mg every 3 days and reached the therapeutic level at 10 to 20 days. Observe the time, frequency, classification and severity of adverse reactions. Results: The rates of adverse reactions in fast-acting group and conventional plus group were 41.54% and 38.46%, respectively, and their durations were similar. Conclusion: The rapid dosage of topiramate is safe.